Mr. Wit has been a member of the Board of Directors since November 1999. He currently serves as our Executive Chairman. He was CEO from June of 2002 until June 2017. Previously he was the President of Corporate Finance at Noesis Capital Corp, Boca Raton, Florida, a NASD member firm, from March 1995 until May 2002. Prior to 1994 Mr. Wit was the CEO for DMV, USA, the American subsidiary of Campina Melkunie, a Dutch multi-billion dollar food and pharmaceutical ingredients company. He also served as Vice President International Operations for Duphar, a pharmaceutical company in Holland. Mr. Wit graduated from Nyenrode, a business university in Holland.
Mr. Smith has been an executive officer and member of the Board of Directors since 1997. He currently serves as our Executive Vice Chairman. He served as President and Chief Technology Officer from May 1997 until August 2000 and thereafter as Chairman and Chief Technology Officer until June 2017. From December 1995 to May 1997, he was Director of Operations for Global Communications Group. Mr. Smith received a B.S. from Purdue University.
Gary A. Shangold, MD, FACOG, CPI is founder and president of the consulting firm Convivotech, LLC, and of the start-up specialty pharmaceutical company InteguRx Therapeutics LLC. Gary joined the OmniComm Systems board in July 2014. He has previously served in various capacities with a number of other pharmaceutical companies: chief medical officer at Xanodyne Pharmaceuticals Inc.; president and CEO of NovaDel Pharma Inc.; vice president and regulatory head of drug development at Johnson & Johnson Pharmaceutical Research & Development LLC; senior director of gynecologic and reproductive clinical research at RW Johnson Pharmaceutical Research Institute; and medical director at Serono Laboratories Inc. Gary also served as Chair of the Board of Trustees for the Association of Clinical Research Professionals and currently serves on their Nominating and Executive Committees. Gary’s extensive clinical experience brings a deep industry perspective to the OmniComm Board that enables him to advise the board on regulatory and drug development issues surrounding the clinical trial industry.
Adam Cohen (b.1952) graduated in Pharmacy and Medicine from Leiden University. He subsequently joined the department of Clinical Pharmacology of the Wellcome Research Laboratories where he obtained experience in early drug development as well as larger trials. He obtained a PhD degree from Leiden University (1986). He spent a training period in internal medicine and nephrology in King’s College Hospital London. Since 1987, he has been director of the Centre for Human Drug Research (CHDR), a research centre for early drug development and proof of concept studies in healthy subjects and patients. He is professor of Clinical Pharmacology at Leiden University and has a clinical attachment at the department of nephrology at Leiden University Medical Centre. Between 1999 and 2011 he was vice-chairman of the Central Ethics Committee and the Competent Authority (CCMO) of the Netherlands and is European editor of the British Journal of Clinical Pharmacology as well as a member of the Health Council of the Netherlands and the Council for Medical Sciences of the Royal Academy of Sciences of the Netherlands. Adam Cohen was also one of the founders of Promasys BV, which was recently acquired by OmniComm Systems.
Mr. Schweitzer has been a member of the Board of Directors since August 2013. Mr. Schweitzer spent his career in the financial services industry as head of lending divisions at money center and major regional banks, Regional President of two major regional banks, and CEO and Chairman of two community banks. He also served as President of a major regional investment bank. He is a graduate of the U.S. Naval Academy, served on nuclear submarines and retired with the rank of Captain, and holds an MBA from the University of North Carolina. He currently serves on three other public company boards and is chairman of two.
Mr. Johnson currently serves as our Chief Executive Officer and President. He served as our President & Chief Operating Officer from June 2010 until June 2017. He is responsible for providing effective leadership, direction in planning, oversight of all business development and operational and technology functions, and managing and directing all Corporation activities. Prior to June 2010, he served as Chief Operating Officer and Executive Vice President of Business Development since April 2008, managing the delivery and execution of all operational activities including sales, marketing, professional services and clinical services and support. Mr. Johnson joined OmniComm as Senior Vice President of Business Development in September 2006 and was initially responsible for global sales & marketing and client services & support. Prior to joining OmniComm Systems, Inc., he spent 7 years managing business development for the Oracle Clinical Applications group for the East Coast. He has more than 25 years of industry experience specific to clinical trials and electronic data capture (EDC), having held various positions of increasing responsibility for Oracle, PHT Corp., Clinical Data Solution and Pfizer Pharmaceuticals. Mr. Johnson received his B.S. in Microbiology from the University of Massachusetts Amherst.
Mr. Vickers joined OmniComm in October 2011 as the Vice President of Finance. In October 2012 he was promoted to Chief Financial Officer. Prior to joining OmniComm, Mr. Vickers was with Ocwen Financial Corporation, a publicly traded diversified financial services holding company, where he served in positions of increasing responsibility, most recently as Director, Servicing Operations. Previously Mr. Vickers was Vice President, Operations for S&J and Vice President, Financial Operations for Precision Response Corporation. Mr. Vickers has undergraduate degrees in Finance and Accounting and a Master of Taxation from Florida Atlantic University, an MBA from the University of Miami and is a Chartered Financial Analyst Charterholder.
Mr. Fontenault has served as the Company's Chief Operating Officer since June 2017. He served as our Senior Vice President of Operations from October 2014 until June 2017. A clinical data operations and data systems executive, he brings more than 25 years of pharmaceutical industry experience. Prior to joining OmniComm, Mr. Fontenault was Vice President, Operations at ER Squared, providing strategic eClinical business process and technology change management and adoption services to large and small sized sponsors and CROs. Prior to ER Squared, Mr. Fontenault was Executive Director and Global Head of Clinical Data Management and Technology at Kendle International (INC Research) where he was responsible for a staff of 500 in 13 locations worldwide. Prior to Kendle, Mr. Fontenault held positions of increasing responsibility at Bayer.
Mr. Howells has served as the Company’s Chief Technology Officer since June 2017. He served as our Senior Vice President of Development from April 2012 until June 2017. He joined OmniComm in January 2011, with responsibility for the development and forward direction of the company’s products. Mr. Howells has over 20 years of experience in building and implementing clinical research applications, including 5 years as head of development for Oracle’s pharmaceutical application suite and 5 years as head of development for Medidata Solutions. This encompasses applications for clinical data management, EDC, medical dictionary coding, safety, trial planning and trial budgeting. Mr. Howells has a degree in physics from Oxford University, England.
Dr. van der Post has served as the Company’s Chief Commercial Officer since June 2017. He served as our Senior Vice President of Business Development from June 2013 until June 2017. He has been working in both the preclinical and clinical development arena for over 14 years. Prior to joining OmniComm, he worked for Oracle’s Health Sciences Global Business Unit as well as Medidata Solutions. He obtained his PhD from the University of Liverpool (UK) and his Master of Science from Salford University (UK). He currently leads OmniComm’s global sales and marketing teams.
Dr. Rollinger is Managing Director of OmniComm Europe, located in Bonn, Germany. She has oversight of all business activities of this entity. Before joining OmniComm she was Director Clinical Services and Senior Consultant at DATATRAK. Prior to that she served as Project Manager, CRA and Sales Representative at Medifacts International Medical Consultants, Padcom Clinical Research, Dolorgiet Pharmaceuticals and Spitzner Pharmaceuticals. Dr. Rollinger received a PhD from Rheinische Friedrich-Wilhelms-Universität Bonn in Biology and Biochemistry. She has more than 25 years of experience in the pharmaceutical industry with a focus on clinical trial management and EDC.
Ken Light is the Executive Vice President of Corporate Strategy since June 2017. Previously he was the Executive Vice President of Operations and Professional Services at OmniComm. Prior to joining OmniComm, Mr. Light was a Solutions Partner at BusinessEdge Solutions, Inc. where he oversaw the delivery of technology, strategy and process improvement services for pharmaceutical and life sciences companies. Prior to that he was Practice Director, Life Sciences Consulting for Oracle Corporation where he oversaw clinical software implementation activities for major pharmaceutical and life sciences organizations. Before joining Oracle, he was Practice Director, Clinical Technology for First Consulting Group. Mr. Light received a B.S. from SUNY Binghamton and an M.S., Computer Science from Fairleigh Dickinson University and has delivered a multitude of educational industry presentations at meetings such as the DIA, EDC and Beyond, ACRP and the eClinical Forum.